Serum Institute picks up 20% in needle-free tech company IntegriMedical
Vaccine major Serum Institute of India has acquired 20 per cent stake in medical device company IntegriMedical to advance needle-free injection technology, for an undisclosed amount.
The technology addresses needle-phobic patients, helping
increase patient compliance, reduce needle-stick injuries, and enhancing the
efficacy of liquid medication via needle-free dispersion, a note from the
company said.
Serum Institute of India (SII) has been investing in backend
companies and had in August 2021, bought out the Indian partner in SCHOTT
Kaisha, securing its supplies of pharma packaging products, including vials,
syringes, ampoules and cartridges used to package life-saving medication.
IntegriMedical has developed a US patented needle-free
injection system (N-FIS) that utilises high-velocity jet stream using
mechanical power to effectively and consistently administer biologics and
drugs, the note said. N-FIS will be available in the Indian private market,
offering patients and healthcare providers an alternative to traditional
needle-based injections, it added, without giving timelines.
Adar Poonawalla, SII Chief Executive said, they were
constantly seeking opportunities to invest in technologies that aligned with
its mission. “IntegriMedical’s Needle-Free
Injection Systems represent a significant advancement in drug delivery and
we envision a needle-free solution to deliver vaccines,” he said, adding that
it would “potentially revolutionize the way we administer vaccines”.
Comments
Post a Comment